首页> 外文期刊>Urologic oncology >Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy
【24h】

Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy

机译:癌干细胞标志物CD24和CD44在尿路上皮癌异种移植和根治性膀胱切除术患者中的表达及预后意义

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: To evaluate CD24/CD44/CD47 cancer stem cell marker expressions in bladder cancer (BCa) and provide data on their prognostic significance for clinical outcome in patients undergoing radical cystectomy (RC). Material and methods: Primary BCa tissue was used for xenograft studies. A tissue microarray was prepared using specimens from a cohort of 132 patients. All patients underwent RC for urothelial BCa between 2001 and 2010. Expression of CD24, CD44, and CD47 was examined in primary samples and xenografts by fluorescence-activated cell sorting. Populations of CD24low- and CD24high- expressing cells were sorted and evaluated for tumorigenicity in vivo. Tissue microarray was analyzed for CD24/CD44 staining intensity and tumor-specific vs. stromal cell staining. Associations with BCa survival, BCa stage, and lymph node status were evaluated by univariate and multivariate analyses. Results: CD24 and CD44/CD47 expressions mark distinct cell populations within the normal urothelium as well as in BCa. CD24high/low expression was not sufficient to characterize CD24 as a BCa-initiating marker in in vivo primary xenotransplants. CD24 and CD44 expressions correlated with lower cancer-specific survival in patients. However, multivariate analyses of CD24 or CD44 did not demonstrate significantly increased hazards for cancer-specific death if analyzed together with stage, grade, and nodal status of patients. Conclusions: Cancer stem cell markers CD24/CD44/CD47 are differentially expressed in cells of urothelial BCa in patients undergoing RC and influence cancer-specific survival of patients. Further evaluation of CD24/CD44/CD47 protein expression could be of high therapeutic value in BCa. However, both CD24 and CD44 expressions cannot be regarded as independent prognostic parameters for patients undergoing RC.
机译:目的:评估膀胱癌(BCa)中CD24 / CD44 / CD47癌症干细胞标志物的表达,并提供其对行根治性膀胱切除术(RC)的患者临床预后的意义。材料和方法:原发性BCa组织用于异种移植研究。使用来自132名患者的样本制备了组织微阵列。在2001年至2010年期间,所有患者均接受了尿路上皮BCa的RC。通过荧光激活细胞分选检查了原代样品和异种移植物中CD24,CD44和CD47的表达。对CD24低表达和CD24高表达细胞群体进行分类,并评估其体内致瘤性。分析组织微阵列的CD24 / CD44染色强度以及肿瘤特异性与基质细胞染色。通过单因素和多因素分析评估与BCa生存,BCa分期和淋巴结状态的关联。结果:CD24和CD44 / CD47表达标志着正常尿路上皮以及BCa中不同的细胞群。 CD24高/低表达不足以将CD24表征为体内原代异种移植中的BCa起始标记。 CD24和CD44表达与患者较低的癌症特异性生存率相关。但是,对CD24或CD44进行多变量分析,如果与患者的分期,等级和淋巴结状态一起进行分析,则没有显示出因癌症特异性死亡的危险显着增加。结论:癌症干细胞标志物CD24 / CD44 / CD47在接受RC的患者的尿路上皮BCa细胞中差异表达,并影响患者的癌症特异性生存。 CD24 / CD44 / CD47蛋白表达的进一步评估可能对BCa具有高治疗价值。然而,对于患有RC的患者,不能将CD24和CD44的表达都视为独立的预后参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号